Icahn School of Medicine, Champions Oncology Evaluating Breast Cancer PGx Technology | GenomeWeb

NEW YORK (GenomeWeb) – The Icahn School of Medicine at Mt. Sinai and Champions Oncology today announced the start of a clinical trial to evaluate the use of the firm's Champions TumorGrafts technology in 100 patients with triple-negative breast cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.